Generics & Biosimilars | Association for Accessible Medicines

New White Paper - Read AAM Report on Drug Shortages

NEW: Drug Shortages in the U.S. 2023 Report

IQVIA Institute’s new report highlights important factors including the critical role that unsustainable reimbursement plays in causing and contributing to drug shortages.

View Press Release
Coming to Access! 2024?

Sign up by November 17 and save $100 off full-pass registration. Meet the leaders and decision-makers who are shaping the future of generics and biosimilars. February 5–7, 2024, Tampa, Florida.

Watch Video
NEW: 2023 U.S. Generic & Biosimilar Medicines Savings Report

Savings continue to grow with $408 billion saved in 2022 for the U.S. health care system, including patients, employers and taxpayers. Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are an integral part of the U.S. health care system.

Read Press Release
AAM White Paper on Shortages

Drug shortages, which hit crisis proportions between 2010 and 2011, can be a challenge for manufacturers, providers, and patients. Due to aggressive efforts by industry and the Food and Drug Administration (FDA), the incidence of shortages has declined, but recent reports suggest a rise in shortages in 2023.

Read Report
What Do You Take #4GRxANTED?

The generic and biosimilar industry is working with Direct Relief to donate doses of medicines across the U.S. to people in need. You can be part of this collective effort by recording a short video on what you take for granted and sharing on social media with #4GRxANTED and @4GRxANTED.

Learn More
PBMs Are Blocking Patient Access to Biosimilar Insulin

A new report from AAM’s Biosimilars Council shows that even as patient demand for biosimilar insulin has grown dramatically, PBMs are continuing to restrict patient access and drive up drug prices.

Read Blog
"You guys make such a huge difference that you don't get credit for."

Mark Cuban on generic medicines.

View Video
Study Finds Middlemen Increasingly Block Patient Access to New Generics

New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.

Read Press Release